News

Astellas Pharma Inc. (“Astellas”) has launched a “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. This section was developed to recruit potential parties who wish to acquire Astellas’ R&D programs that were terminated for strategic reasons. Astellas has been working on the effective utilization of its assets from programs for which it has terminated R...

Includes five oral presentations that collectively explore the use of gilteritinib across the FLT3mut+ AML care continuum TOKYO, November 16, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition...

TOKYO, November 11, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) announced that it has decided today, to absorb and merge (“the Merger”) our wholly owned subsidiaries, Astellas Pharma Tech Co., Ltd. (“Astellas Pharma Tech”) and Astellas Green Supply, Inc.(“Astellas Green Supply”) Since the Merger is simple/short form absorption merger of our...

Enzalutamide is now NMPA-approved for both non-metastatic and metastatic castration-resistant prostate cancer TOKYO, November 6, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration (NMPA) has approved XTANDI® (enzalutamide soft capsules) for the treatment of adult men with non...